
Home » OSI PHARMACEUTICALS REPORTS PSN9301 TRIAL DATA
OSI PHARMACEUTICALS REPORTS PSN9301 TRIAL DATA
June 13, 2006
OSI Pharmaceuticals has reported positive results from its Phase IIa proof-of-concept study with its dipeptidyl peptidase-IV (DPIV) inhibitor, PSN9301.
The study demonstrated that with prandial (with-meal) dosing, 14-day administration of PSN9301 reduced blood glucose levels in patients with Type 2 diabetes and was generally well-tolerated with no episodes of hypoglycemia (low blood glucose). Also presented were preclinical data on novel, orally available agonists of the G-protein coupled receptor GPR119 for the potential treatment of obesity, diabetes and associated metabolic disorders.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
10Mar
-
16Mar
-
18Mar
-
23Mar
-
30Mar
-
06Apr